HK1246306A1 - 聚乙二醇化的il-11的组合物和方法 - Google Patents

聚乙二醇化的il-11的组合物和方法 Download PDF

Info

Publication number
HK1246306A1
HK1246306A1 HK18105366.5A HK18105366A HK1246306A1 HK 1246306 A1 HK1246306 A1 HK 1246306A1 HK 18105366 A HK18105366 A HK 18105366A HK 1246306 A1 HK1246306 A1 HK 1246306A1
Authority
HK
Hong Kong
Prior art keywords
polypeptide chain
peg moiety
peg
pharmaceutical composition
induced
Prior art date
Application number
HK18105366.5A
Other languages
English (en)
Chinese (zh)
Inventor
K‧余
Q‧周
M‧福克
J‧Y‧刘
J‧Y‧劉
Original Assignee
阿瓦隆生物制品有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 阿瓦隆生物制品有限公司 filed Critical 阿瓦隆生物制品有限公司
Publication of HK1246306A1 publication Critical patent/HK1246306A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5431—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2073—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK18105366.5A 2015-03-03 2016-03-01 聚乙二醇化的il-11的组合物和方法 HK1246306A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562127748P 2015-03-03 2015-03-03
US62/127,748 2015-03-03
PCT/US2016/020294 WO2016140983A1 (en) 2015-03-03 2016-03-01 Compositions and methods for pegylated il-11

Publications (1)

Publication Number Publication Date
HK1246306A1 true HK1246306A1 (zh) 2018-09-07

Family

ID=56848663

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18105366.5A HK1246306A1 (zh) 2015-03-03 2016-03-01 聚乙二醇化的il-11的组合物和方法

Country Status (7)

Country Link
US (4) US10335492B2 (cg-RX-API-DMAC7.html)
EP (1) EP3265479A4 (cg-RX-API-DMAC7.html)
JP (2) JP6937984B2 (cg-RX-API-DMAC7.html)
CN (1) CN107849108A (cg-RX-API-DMAC7.html)
HK (1) HK1246306A1 (cg-RX-API-DMAC7.html)
TW (2) TWI849231B (cg-RX-API-DMAC7.html)
WO (1) WO2016140983A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6937984B2 (ja) * 2015-03-03 2021-09-22 ナンシャ・バイオロジックス・（ホンコン）・リミテッドＮａｎｓｈａ Ｂｉｏｌｏｇｉｃｓ （Ｈｏｎｇ Ｋｏｎｇ） Ｌｉｍｉｔｅｄ ペグ化ｉｌ−１１の組成物および方法
WO2023055081A1 (ko) * 2021-09-28 2023-04-06 한양대학교 산학협력단 암 치료용 글리시리진-분지형 폴리에틸렌글리콜 컨쥬게이트
CN118388578B (zh) * 2024-04-01 2025-01-24 北京大学口腔医学院 一种用于聚乙二醇化蛋白质的方法、非共价聚乙二醇化蛋白及含有其的蛋白质药物和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
CN1316436A (zh) * 2000-04-06 2001-10-10 赵剑 水溶性缓释重组蛋白质的制备方法
PL380269A1 (pl) * 2002-12-26 2007-01-08 Mountain View Pharmaceuticals, Inc. Koniugaty polimerowe cytokin, czynników wzrostu, hormonów polipeptydowych i ich antagonistów o zachowanej zdolności do wiązania receptora
JP2005281302A (ja) * 2004-03-03 2005-10-13 Astellas Pharma Inc 修飾インターロイキン−１１及びそれを含有する医薬組成物
WO2005085283A1 (ja) * 2004-03-03 2005-09-15 Yamanouchi Pharmaceutical Co., Ltd. 修飾インターロイキン−１１及びそれを含有する医薬組成物
JP5602738B2 (ja) * 2008-08-25 2014-10-08 ビロメッド カンパニー， リミテッド インターロイキン−１１類似体を含む生体ポリマー結合体
CA2764449A1 (en) * 2009-06-03 2010-12-09 Regado Biosciences, Inc. Nucleic acid modulators of glycoprotein vi
EP2478066B1 (en) * 2009-09-18 2017-04-26 Protherics Medicines Development Limited Bab triblock polymers having improved release characteristics
US8927488B2 (en) * 2010-05-17 2015-01-06 Cebix, Inc. Pegylated C-peptide
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
WO2013020079A2 (en) * 2011-08-04 2013-02-07 Nektar Therapeutics Conjugates of an il-11 moiety and a polymer
WO2014008242A1 (en) * 2012-07-03 2014-01-09 The Trustees Of Columbia University In The City Of New York The use of interleukin-11 to protect against ischemia and reperfusion injury
US8963121B2 (en) * 2012-12-07 2015-02-24 Micron Technology, Inc. Vertical solid-state transducers and high voltage solid-state transducers having buried contacts and associated systems and methods
US20160000901A1 (en) 2013-03-05 2016-01-07 Shifa Biomedical Compositions and Methods for the Production of Virus-Like Particles
CN109498815B (zh) * 2013-12-30 2022-07-22 江苏众红生物工程创药研究院有限公司 重组人激肽释放酶的化学修饰物及其应用
JP6937984B2 (ja) * 2015-03-03 2021-09-22 ナンシャ・バイオロジックス・（ホンコン）・リミテッドＮａｎｓｈａ Ｂｉｏｌｏｇｉｃｓ （Ｈｏｎｇ Ｋｏｎｇ） Ｌｉｍｉｔｅｄ ペグ化ｉｌ−１１の組成物および方法

Also Published As

Publication number Publication date
JP2021176875A (ja) 2021-11-11
EP3265479A4 (en) 2018-11-14
TWI708611B (zh) 2020-11-01
US20190365908A1 (en) 2019-12-05
TW202103728A (zh) 2021-02-01
US10881739B2 (en) 2021-01-05
TW201703793A (zh) 2017-02-01
EP3265479A1 (en) 2018-01-10
US20180036418A1 (en) 2018-02-08
US20190365909A1 (en) 2019-12-05
US20210268117A1 (en) 2021-09-02
US10946103B2 (en) 2021-03-16
JP2018508580A (ja) 2018-03-29
JP6937984B2 (ja) 2021-09-22
WO2016140983A1 (en) 2016-09-09
US10335492B2 (en) 2019-07-02
TWI849231B (zh) 2024-07-21
CN107849108A (zh) 2018-03-27
US11931417B2 (en) 2024-03-19

Similar Documents

Publication Publication Date Title
EP2233504B1 (en) An erythropoietin mimetic peptide derivatives and its pharmaceutical salt, the preparation and uses thereof
Wu et al. Precise and combinatorial PEGylation generates a low-immunogenic and stable form of human growth hormone
AU2012263100A1 (en) Stable liquid formulation of etanercept
RU2447083C1 (ru) НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
US11931417B2 (en) Methods of preparing a pegylated human IL-11 composition
WO2013138730A1 (en) Polymeric conjugates of c1-inhibitors
WO2012021088A1 (en) A novel conjugate of granulocyte colony-stimulating factor (g-csf) with polyethylene glycol
AU2017246404B2 (en) Conjugated C1 esterase inhibitor and uses thereof
JP2025521100A (ja) 抗Ｎｅｃｔｉｎ－４抗体薬物複合体を含む医薬組成物及びその使用
EP4628103A1 (en) Anti-her3 antibody-drug conjugate composition and pharmaceutical use thereof
US20250367311A1 (en) Pharmaceutical composition containing an antibody-drug conjugate and use thereof
DE60313786T2 (de) Poly(ethylen glykol)-konjugate von insulinähnlichem wachstumfaktor bindenden protein-4
WO2019211842A1 (en) Long-acting human growth hormone-antagonists and methods of producing the same
KR101104574B1 (ko) 폴리에틸렌글리콜로 화학적으로 수식된 인간 성장 호르몬, 이의 제조방법 및 용도
CN101277715A (zh) 神经变性疾病的治疗
Wang et al. Effects of linear and branched polyethylene glycol on PEGylation of recombinant hirudin: Reaction kinetics and in vitro and in vivo bioactivities
US20250269045A1 (en) Unique pegylated granulocyte colony stimulating factor, methods of use and preparation thereof
CN120957752A (zh) 一种含有糖皮质激素受体激动剂的药物偶联物的药物组合物
CN105367629B (zh) 一种促红细胞生成素模拟肽以及其制备方法和用途
JP2008512385A (ja) アルブミンの内因的に形成された結合体
Yu Modification of recombinant human interleukin-11 to enhance pharmacologic properties and therapeutic potential
KR20180087864A (ko) 신규 엑세나타이드 변이체-고분자 복합체
KR20040066712A (ko) 인간 성장 호르몬의 결합체